About the Company
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ACRX News
Recap: AcelRx Pharmaceuticals Q1 Earnings
AcelRx Pharmaceuticals (NASDAQ:ACRX) reported its Q1 earnings results on Wednesday, May 10, 2023 at 04:05 PM. Here's what investors need to know about the announcement. AcelRx Pharmaceuticals beat ...
Interview with the Director, President and CEO: AcelRx Pharmaceuticals, Inc. (ACRX)
The Wall Street Transcript is a completely unique resource for investors and business researchers.
AcelRx Pharmaceuticals
A special interest's lobbying activity may go up or down over time, depending on how much attention the federal government is giving their issues. Particularly active clients often retain multiple ...
AcelRx Pharmaceuticals Inc (R5XA.BE)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Adrian Adams's Net Worth
Adrian Adams has an estimated net worth of $3.88 Million. This is based on reported shares across multiple companies, which include NEUROLOGIX INC/DE, NEUROCRINE BIOSCIENCES INC, IMPEL ...
Apellis Pharmaceuticals Inc (APLS) Stock: What the Analysts are Saying
Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.” The public float for APLS is 98.84M, and at present, short sellers hold a 10.56% ...
Daniel Janney's Net Worth
Daniel Janney has an estimated net worth of $440 Million. This is based on reported shares across multiple companies, which include IMMUNE DESIGN CORP., ZS Pharma, Inc., SUTRO BIOPHARMA, INC ...
CRVS Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers ...
NRBO NeuroBo Pharmaceuticals, Inc.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241 ...
Madrigal Pharmaceuticals, Inc. (MDGL)
CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday ...
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
AcelRx Pharmaceuticals Inc (R5XA.SG)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...